Clinical Trial Update: Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase [Phase 3]

View source ↗

Summary

A 52-week extension Phase 3 trial assessing the safety of the buprenorphine transdermal patch for osteoarthritis pain; the study was terminated with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• Buprenorphine transdermal patch (buprenorphine)

Snippet

Sponsor: Purdue Pharma LP | Conditions: Osteoarthritis | Phase 3 | Status: TERMINATED | Results posted: 2010-09-23